Vascular cell adhesion molecule 1 (VCAM-1)
cell adhesion molecule 1, and vascular cell adhesion molecule 1 (VCAM-1). These are the only known immunoglobulin-like receptors for leukocyte integrins, a family of heterodimeric proteins essential to leukocyte extravasation and thus to immune surveillance. They have two rather than one pair of cysteine residues in the functionally important N-terminal domain essential for binding to the integrin ligand; the four cysteine residues are conservatively spaced. Because these cell adhesion molecules are essential to leukocyte recruitment and thus to the inflammatory and immune response, they have generated interest as potential targets of antiinflammatory drugs.
VCAM-1 is induced on endothelial cells in culture by inflammatory stimuli such as tumor necrosis factor, interleukin 1, and lipopolysaccharide. It is up-regulated in both early and late atherosclerotic plaques (1) (2) (3) (4) . It binds to a4 integrins on mononuclear leukocytes, including B and T lymphocytes, monocytes, eosinophils, and basophils, but not neutrophils (5) . The major form is composed of seven immunoglobulin-like domains, of which domains 1-3 are strikingly homologous in both structure and function to domains [4] [5] [6] (1, 6) . Rotary shadowing electron microscopy of recombinant soluble sevendomain VCAM-1 indicates an extended, slightly bent rod-like structure for the molecule (10) . Structure/function studies indicate that domain 1 (or the homologous domain 4) is most important for binding, with the contiguous domain 2 (or domain 5) required at least for stabilization of structure in both recombinant versions and proteolytic cleavage fragments of the molecule (7) (8) (9) . Although most monoclonal antibodies that block function of VCAM-1 map to domain 1 or 
its homologue
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. domain 4, two distinct functional epitopes map to domain 2, suggesting that domain 2 may have a role in ligand binding. Mutagenesis studies directed at domain 1 have identified two sets of residues involved in binding, one centered at the required residue Asp-40, and one less important at residues G64NEH (10, 11) .
We report here the crystal structure of a fragment containing the N-terminal two domains of VCAM-1, the only known member of its immunoglobulin superfamily subclass to be so defined. § The structure consists of two concatenated immunoglobulin modules. The functionally important residue Asp-40 is located at the i+3 position of a (3-turn on the corner of the projecting C-D loop of domain 1. A peptide scan of domains 1 and 2 revealed that only sequences containing this loop were capable of consistently inhibiting VCAM-1-a4l31 integrin interaction. A cyclic peptide designed to mimic the sequence and structure of this local region showed a marked increase in potency compared to linear peptides and cyclic peptides modified in amino acid sequence.
MATERIALS AND METHODS
Production of Selenomethionine-Labeled VCAM-D1D2.
Seleno-L-methionine (Sigma)-containing VCAM-D1D2-immunoglobulin was prepared by the published labeling protocol (12) , which we adapted for cells growing on collagencoated beads. VCAM-D1D2-immunoglobulin fusion protein was purified from the supernatant, and functional VCAM-1 fragment comprising the N-terminal two domains (referred to here as VCAM-D1D2) was prepared by limited papain digestion as described (13) .
Crystallization and Data Collection. VCAM-D1D2 was crystallized as described (13 (25) . A schematic representation of the structure is shown in Fig. 1A , and an assignment of the 1-strands is given in Fig. 2 . Domain 1 (residues 1-89) belongs to a newly identified I-set of immunoglobulin fold (28) . This "intermediate" set resembles a V-set immunoglobulin fold in having conserved conformations for strand A and for the A-B and E-F loops, but it also resembles the Cl-set in lacking the C" strand. In addition to the disulfide bond commonly found within the core of immunoglobulin domains (Cys-23-Cys-71 in VCAM-D1D2), another disulfide bond is seen at the edge of the domain between Cys-28 and Cys-75. This additional disulfide bond brings the B-C and F-G loops in close proximity so that the tip of the domain becomes very compact (Fig. 1A) . The most protruding feature in domain 1 is the C-D loop, near the opposite end of the domain, which carries the functionally important residue Asp-40 (10, 11). The structure of this loop, shown in Fig. 1B Data sets Pb-1 and Pb-2 were used for isomorphous and anomalous differences, respectively. Rmerge = YhYiIIhi -Ihl/lhiIhi. Rder = YiIFPH -FpI/IiFp. PP, phasing power (mean value of heavy atom structure amplitudes divided by residual lack-of-closure error). Rc, Cullis R factor for centric reflections. loop appears to be an extremely important structural feature of the integrin-binding subclass of the immunoglobulin superfamily. Domain 2 (residues 90-195) is best described as a C2-set immunoglobulin fold (28) . It contains 106 amino acid residues and is therefore considerably larger than the typical C2-set domains, which generally contain <90 residues. (27) . Sequence of the N-terminal part of the C-D loop (residues [37] [38] [39] [40] [41] [42] [43] ) is highlighted and paired with the sequence of the most potent cyclic peptide. Residue Tyr-89 is highlighted as well.
in size is reflected in the loop structure-the loops in domain 2 of VCAM-D1D2 are more extensive than those in related structures. They are also rather mobile and characterized by high temperature factors. Moreover, in contrast to domain 1, the structures of the two copies of domain 2 differ in the loop regions. In general, these differences are small and can be attributed to different packing environments. The open conformation of the F-G loop of domain 2 is unusual; it is, nevertheless, well defined by electron density in both molecules. Parts of this loop (residues 178-180) form an antiparallel 13-sheet with residues 1-3 of domain 1 of a crystallographically related molecule; this interaction may influence the loop conformation.
The interface between domains 1 and 2 is mainly hydrophobic. The total buried surface area, as calculated with ACCESS is 800 A2. This area is smaller than that in CD4-D1D2 [1100 A2 (29) ] but larger than that in CD2 [400 A2 (25) ]. As shown in Fig. 3 , the angle between domains 1 and 2 differs by 120 in the two molecules. This difference is mainly absorbed by residue Tyr-89, which has the only noticeably different mainchain conformation among the residues that connect the two domains. This appears to justify the designation pivot for Tyr-89.
The relative orientation of the 13-barrels in the two domains is different from CD4-D1D2 or CD2. In VCAM-D1D2, the FIG. 3 . Stereoview of the two crystallographically independent molecules of VCAM-D1D2. Molecule B has been superimposed onto molecule A using only C0 atoms of domain 1. This view emphasizes the different angles between the domains in the two molecules. Molecules A and B are represented by solid and broken lines, respectively. Some residues are labeled. The figure was prepared by using MOLSCRIPr (30) .
angle for rotation of domain 1 onto domain 2 is 1300, whereas in CD4-D1D2 and CD2 this angle is 1600. As a result, the planes of the (3-barrels in VCAM-D1D2 appear to be almost perpendicular to each other instead of roughly parallel.
Peptide Studies. To search for peptides that would interfere with the interaction of VCAM-1 with its counterreceptor a431, we screened a panel of 94 peptides, each 12 amino acids long, designed to scan the entirety of VCAM domains 1 and 2. Each peptide was assayed twice at approximately 1.0 and 0.5 mM by the assay described in Materials and Methods. Two peptides inhibited well at 1 mM in two separate assays: (biotin-SGSG)-WRTQIDSPLNGK and (biotin-SGSG)-TQIDSPLNGKVT, representing amino acids 35-48 of VCAM-1 (Fig. 4A) . Interestingly, these peptides include residue Asp-40, which was implicated in binding to leukocyte a4031 integrin by site-directed mutagenesis of VCAM-1 (10, 11) . Each of these peptides fully includes the protruding C-D loop.
Purified peptides representing this approximate region were also assayed and showed varying degrees of activity as indicated in Fig. 4A . The peptide ESPFFSWRTQIDSPLN inhibited as well as the crude peptides, but a pentamer, QIDSP, was inactive. However, a cyclic version of this sequence, CQID-SPC, was the most potent peptide tested. Titration of this peptide shows a clear dose-response relationship (Fig. 4B) . A version offset in sequence by 1 amino acid residue, CIDSPLC, was markedly less active, and an unrelated peptide, CPITVKC, was completely inactive, as were various other cyclic peptides tested in parallel (Fig. 4A) . Cyclic peptide CQIDSPC closely mimics loop C-D in the crystal structure of VCAM domain 1.
DISCUSSION
We have demonstrated that a cyclic peptide can effectively block the adhesion between VCAM-D1D2 and a4f31 integrin. The sequence of the cyclic peptide CQIDSPC closely mimics that of the C-D loop in domain 1 of VCAM-D1D2. The crystal structure shows that this loop protrudes from the molecule and is easily accessible for contact. The functionally important residue, Asp-40, is located at the corner of the loop. If one were to mutate both Thr-37 and Leu-43 residues into cysteines, a cyclic peptide could be formed easily without disturbing the loop structure significantly. synthetic cyclic peptide we have studied adopts a conformation very similar to that part of the C-D loop. The lack of activity of the linear peptide QIDSP indicates that the spatial constraint provided by cyclization is essential for mimicking this part of the C-D loop structure and thus is essential for activity. The failure of cyclic peptide CIDSPLC to inhibit binding, in spite of mutagenic data indicating that residue Gln-38 can be successfully substituted by alanine in the binding site of the intact protein (10) , suggests that the positioning of the residues in the loop is important for activity.
The region that includes residues G64NEH may also be important for ligand binding (10) . This sequence is located in the E-F loop of domain 1, in close proximity to the C-D loop (see Fig. 1A ). It might interact directly with the integrin ligand, or it might play an indirect role by stabilizing the structure of Medical Sciences: Wang et aL the C-D loop. There is an extensive network of hydrogen bonds between the C-D and E-F loops, some of which involve the side chain of His-67.
It is known that some members of this subclass of the immunoglobulin superfamily are subverted as viral receptors: murine VCAM-1 for encephalomyocarditis virus (31) and human ICAM-1 for human rhinovirus (HRV) (32) . Cryoelectron microscopy of HRV16, "decorated" with a two-domain fragment of ICAM-1, has shown that the tip of domain 1 of ICAM-1 inserts into a canyon on the virus surface (33) . The unique "extra" disulfide bond in domain 1 of VCAM-1 makes a narrow and compact tip, which may be necessary for this interaction. Since all members of the VCAM-1/ICAM-1 subclass have this additional disulfide bond, such a compact tip may be a general feature in these structures. In the case of ICAM-1, there is evidence that residues in the B-C and F-G loops that are located immediately beyond the additional disulfide bond play a role in virus binding (ref. 33 and references therein). It is conceivable that the disulfide bond pulls these otherwise quite flexible loops together and orients these important residues for recognition.
The structure of VCAM-1 demonstrates that the binding sites of these cell adhesion molecules for integrins and viruses are located on different regions of the molecule, as indicated by previous data (34) . The evidence here, in combination with previous reports that short peptides from fibronectin can also inhibit a4p1 integrin binding (35, 36) , could be the basis for an additional integrin binding sequence motif, analogous to the RGD motif found in ligands of several other integrins (37) . Our results can, in principle, also serve as a model for blocking interactions in related structures, such as the interaction between CD4 and gp120, by designing peptides that mimic loop structures on the surface of these proteins.
Note Added in Proof. While this manuscript was under review, a manuscript by Jones et al. (38) was published, also presenting crystallographic data on VCAM-D1D2. Their protein was produced in Escherichia coli and crystallized in a different space group. The structure is similar to that presented here.
